Similarly, preclinical study on the use of AAV5 vector to deliver human interferon-β (IFN-β) to treat RA also showed a reduction in inflammation and joint damage, which suggests that hIFN-β produced by RA has the potential to be an effective and targeted therapy for RA with minimal off-target effects [63]. This evidence concerns the gene IFNB1 and rheumatoid arthritis.